AIM ImmunoTech (AIM) Q2 2024 earnings summary

Executive summary

• Advanced Ampligen clinical programs in oncology, ME/CFS, and post-COVID conditions, with new positive preclinical data showing slowed tumor growth and improved survival in combination with checkpoint inhibitors.

• Net loss for Q2 2024 was $1.8M, a 63% improvement year-over-year, mainly due to higher interest/other income and lower R&D costs.

• Ongoing commitment to transparency and stakeholder engagement through the CEO Corner platform.

• The company raised $2.05M in a direct offering and expanded its equity line of credit to $15M.

• Cash, cash equivalents, and marketable investments totaled $10.1M as of June 30, 2024.

Financial highlights

• Cash equivalents and marketable securities totaled $10.1 million as of June 30, 2024.

• Research and development expenses were $1.1 million for Q2 and $3.1 million for the first half of 2024, down from $3 million and $5 million in the same periods of 2023.

• General and administrative expenses were $2.6 million for Q2 and $6.4 million for the first half of 2024, compared to $2.6 million and $4.8 million in the same periods of 2023.

• Q2 2024 revenue was $50,000, up $8,000 year-over-year, all from Ampligen cost recovery programs.

• Interest and other income rose to $2.58M in Q2 2024, driven by $2.5M in D&O insurance proceeds.

Outlook and guidance

• Cash position is believed sufficient to fund operations and clinical trials for the next 24 months and through multiple upcoming key milestones.

• Planning to submit a regulatory package to the FDA for post-COVID fatigue in Q4 2024.

• No material revenue is expected in the near term; additional funding may be needed for new or expanded studies.